METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

Slides:



Advertisements
Similar presentations
The management of adverse drug reactions I Ralph Edwards
Advertisements

Safety Reporting IN Clinical Trials
Walsall Healthcare NHS Trust Medicines Management.
Technical Briefing Seminar September |1 | The need for Pharmacovigilance Mary R Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.
Elements of a clinical trial research protocol
Capturing and Reporting Adverse Events in Clinical Research
1 2 Why should I lose time to send a report of adverse drug reactions?
Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.
ADVERSE DRUG REACTIONS Mary Teeling 27 April 2009.
Pharmacoepidemiology: Goals and Methods Sean Hennessy, PharmD, PhD Assistant Professor of Epidemiology & Pharmacology Center for Clinical Epidemiology.
An ABC of Drug-Related Problems RHB Meyboom, M Lindquist, ACG Egberts Drug Safety 2000;22:
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Basic Pharmacovigilance Training
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
DSaRM Advisory Committee May 18, 2005 Active Surveillance for Drug Safety Signals: Past, Present, and Future Mary Willy, Ph.D. Division of Drug Risk Evaluation.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
Pharmaco igilance Mukesh Dheda Byte Conference Centre 19 Jun 2009.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.
Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Reporting of Adverse Drug Reactions: a study among Clinicians
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
ICH V2 An FDA Update Susan Lu Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Biomedical Research.
Study Designs in Epidemiologic
Some Perspectives on a Draft Pharmacovigilance Protocol-reference to HIV/AIDS I Ralph Edwards.
AN INTRODUCTION TO CLINICAL PHARMACOLOGY. BEFORE STARTING DRUG THERAPY, DOCTORS CONSIDER  Whether intervention needed ?  Objective of treatment ? 
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.
Definitions. Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health,
Technical Briefing Seminar September |1 | Methods to study medicine safety problems Mary R Couper Quality Assurance and Safety of Medicines.
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
Unit 2 – Public Health Epidemiology Chapter 4 – Epidemiology: The Basic Science of Public Health.
Managing Hospital Safety: Common Safety Concerns Part 1 of 4.
FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.
Introduction.
Signal identification and development I.Ralph Edwards.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Pharmacovigilance WHO definition
Minimum requirements for Pharmacovigilance in countries.
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,
Types of Studies. Aim of epidemiological studies To determine distribution of disease To examine determinants of a disease To judge whether a given exposure.
1 Overview of Pediatric Safety Reporting and Role of the Committee Pediatric Advisory Committee Meeting November 18, 2005 Solomon Iyasu, M.D., M.P.H. Acting.
Comments on FDA Concept Paper Sidney N. Kahn, MD, PhD President Pharmacovigilance & Risk Management, Inc. Risk Assessment of Observational.
1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.
Effets indesirables des médicaments Cours en partie basé sur source documentaire de l’OMS.
Medicines Act: Pharmacovigilance and the Medical Profession.
Section I General principle of Pharmacology. Where can you get information about general principle of Pharmacology?  Text books:  Katzung, Basic and.
Research Activities at The Boston Collaborative Drug Surveillance Program; Boston University School of Public Health Susan Jick Professor of Epidemiology.
Detection & monitoring of ADR
Present: Disease Past: Exposure
8. Causality assessment:
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
All Wales Therapeutics and Toxicology Centre Cardiff, Wales, UK
Pharmacovigilance (PV)
Pharmacovigilance & Adverse Drug Reactions Dr. Habab Khalid Elkheir
Pharmacy practice experience I
The Need for Pharmaco-Epidemiology in Health Services Research
Adverse Event Analysis
Presentation transcript:

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing Surveillance (PMS) –prescription event monitoring –cohort studies intensive hospital monitoring –case - control studies –record-linkage meta -analysis

Spontaneous reporting Principle The alert health professional connects an undesirable medical event with drug exposure (SUSPICION) Reports suspicion to information collecting centre

ADVERSE DRUG REACTION A reaction which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function WHO definition

ADVERSE EVENT/EXPERIENCE Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment WHO definition

SPONTANEOUS REPORTING Advantages – large population –all medicines –hospital and out-patient care –long perspective –patient analyses possible –inexpensive

SPONTANEOUS REPORTING Disadvantages –underreporting

Reporting varies with: severity of reaction time from market introduction promotional claims promotion of reporting system publicity of specific association

SPONTANEOUS REPORTING Disadvantages –difficult to detect delayed reactions reactions with high background incidence –important details often missing –number of exposed unknown –bias – underreporting

When to report? Early phase Simple message : –Report as soon as you suspect that drug therapy has resulted in a negative, unintended effect. i.e all suspected reactions Speed is essential

What to report? Adverse reactions –Type A –Type B Lack of effect –counterfeiting –resistance –interaction Quality problem Dependence and abuse Poisoning (?) Medical error (?)

What to report? Allopathic medicines –Prescription –OTC Traditional medicines Biologicals incl vaccines

What to report? Alternative approach Serious reactions ( definitions available ) Unexpected reaction (not in product info) Unusually severe reactions New medicines